Research Helps Discover What's Behind Ovarian Cancer Recurrence
Targeted therapies get a jump-start
When asked if he had any targeted therapies in mind already that could be used, Dr. Dottino said, "If you were to look at the two targeted therapies that are currently available for ovarian cancer, it would be the PARP inhibitor and the VEGF inhibitor. However, there maybe be several new therapies that are currently under development in phase 1 and phase 2 trials that could be used one day.
One of the papers that I highlighted in my discussion took a look at patients who had the p53 mutation using AZD1775 with carboplatin in platinum-refractory patients. In the face of the p53 mutation and the following WEE1 pathway, there was a 46 percent response rate. Therefore, it is presumed to be an interested drug, especially since nearly 100 percent of all the patients with ovarian cancer with high-grade serous tumors will likely carry the p53 mutations."